In an SEC filing Friday, the firm said it has signed a five-year procurement contract with the Biomedical Advanced Research and Development Authority (BARDA) which could net the firm as much as $1.6bn.
An initial $200m will cover the supply of two million doses of Emergent’s vaccine NuThrax (anthrax vaccine adsorbed with CPG 7909 adjuvant). However, the contract also includes procurement options for an additional 7.5 million to 50 million doses, valued from approximately $255 million to up to $1.4 billion.
"Emergent is pleased that BARDA has selected NuThrax to address the US government's desire for a next generation anthrax vaccine with an enhanced product profile that includes requiring fewer doses and eliciting a faster immune response," said Daniel J. Abdun-Nabi, Emergent’s CEO.
"We look forward to collaborating with BARDA to further develop NuThrax towards an EUA-eligible product for the SNS and subsequently towards FDA licensure."
NuThrax is comprised of Emergent’s BioThrax (Anthrax Vaccine Adsorbed) combined with the oligodeoxynucleotide compound CPG 7909.
Since 2008 Emergent has been supporting the US Government’s programme to stockpile the product in anticipation of the need for mass vaccinations owing to a future bio-terrorist anthrax attack.